GSK3A and central nervous system cancer: A recent report indicates that transfection with shRNA targeting GSK3α in U87 and A172 glioma cells upregulates GSK3β activity and results in increased levels of c-myc, pERK1/2 (Thr202/Thr204), and cyclin D1 [73].